Our nanoparticle drug-delivery platform reduces local cancer recurrence. By locally and safely delivering chemotherapeutics to residual tumors following a resection surgery, we treat the primary cause of mortality in ovarian, mesothelioma and other peritoneal cancers. This technology accesses a $1B+ (USA) addressable market.
Nanoparticle-based drug delivery systems suffer from poor accumulation in tumors with traditional "active" or "passive" targeting strategies netting a median delivery efficiency of just 0.7% of the injected dose reaching the tumor.
Our solution to this problem is a novel, patented, expansile nanoparticle that employs a unique Materials-Based Targeting strategy to achieve a 50X improvement in delivery efficiency compared to traditional systems. With this improvement, we demonstrate an increase in survival of over 200% compared to clinical standard of care in murine models of peritoneal cancers.